MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bbmt.2019.12.004

Медицинская библиотека · Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors.

Yoshimitsu Makoto, Fuji Shigeo, Utsunomiya Atae, Nakano Nobuaki, Ito Ayumu, Ito Yoshikiyo, Miyamoto Toshihiro, Suehiro Youko, Kawakita Toshiro, Moriuchi Yukiyoshi, Nakamae Hirohisa, Kanda Yoshinobu, Ichinohe Tatsuo, Fukuda Takahiro, Atsuta Yoshiko, Kato Koji, ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative treatment option for patients with aggressive adult T cell leukemia-lymphoma (ATL). Donor human T cell leukemia virus (HTLV) 1 seropositivity is a critical concern when choosing relative donors, as they are not usually recommended due solely to the occurrence of donor-derived ATL. A previous report suggested that allo-HCT with an HTLV-1-seropositive donor increased ATL-related mortality. We updated the risk assessment for choosing an HTLV-1-seropositive allo-HCT donor for ATL. Our current registry data, which include larger numbers of HTLV-1-seropositive donors and longer observation periods, revealed no significant difference in overall survival (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.70-1.24; P = .61) or cumulative incidence of either ATL-related (HR, 0.96; 95% CI, 0.64 to 1.45; P = .80) or non-ATL-related mortality (HR, 0.91; 95% CI, 0.61 to 1.37; P = .66). Similarly, when considering only patients with ATL in complete remission, there was no significant difference in overall survival (HR, 1.02; 95% CI, 0.70 to 1.49; P = .91) or cumulative incidence of either ATL-related (HR, 1.20; 95% CI, 0.66 to 2.20; P=0.54) or non-ATL-related mortality (HR, 0.86; 95% CI, 0.52-1.42; P = .66). These data indicate that selecting HTLV-1-seropositive donors might not be contraindicated for patients with ATL receiving allo-HCT if alternative donors are unavailable. Further risk assessment remains to be performed.

Для цитирования: Yoshimitsu Makoto, Fuji Shigeo, Utsunomiya Atae, Nakano Nobuaki, Ito Ayumu, Ito Yoshikiyo, Miyamoto Toshihiro, Suehiro Youko, Kawakita Toshiro, Moriuchi Yukiyoshi, Nakamae Hirohisa, Kanda Yoshinobu, Ichinohe Tatsuo, Fukuda Takahiro, Atsuta Yoshiko, Kato Koji, ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019. DOI: 10.1016/j.bbmt.2019.12.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.